Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Fedrick Tyler
A vast range of extracellular and intracellular biopolymers, including polyamides, polysaccharides, polyphosphates, polyesters, proteinaceous compounds, and extracellular DNA, may be produced by bacteria, which are regarded as the primary cell manufacturers. Bacterial biopolymers are employed in pathogenicity and are appropriate for use in the pharmaceutical industry due to their wide range of physical and chemical characteristics. When these biopolymer compounds are created by non-pathogenic bacteria, they function as food additives or biomaterials, however when they are derived from pathogenic bacteria, they serve as significant virulence factors. Using synthetic biology to create novel biomaterials, there have been multidisciplinary researches looking at the molecular processes involved in the synthesis of bacterial biopolymers and the discovery of new antimicrobial drug targets.